WASHINGTON, May 09, 2025 (GLOBE NEWSWIRE) -- Nationally ranked securities law firm Cohen Milstein Sellers & Toll PLLC is actively continuing its search for investors willing to serve as lead plaintiff in a securities class action lawsuit filed against Zenas BioPharma, Inc. (NASDAQ: ZBIO). The complaint alleges materially misleading statements made in connection with the company’s September 2024 initial public offering (IPO). The deadline to file a motion for lead plaintiff is June 16, 2025. [Click here for information about joining the class action] If you’d like to discuss this matter or your rights before signing up, please contact Molly J. Bowen, a partner at Cohen Milstein, at (202) 408-4600 or [email protected]. Allegations in the Complaint The lawsuit, filed in the U.S. District Court for the District of Massachusetts, accuses Zenas BioPharma and several underwriters of overstating the Company’s financial runway in its IPO registration materials. Zenas BioPharma projected its available capital would last 24 months, but in its Q3 2024 financial filing, the company admitted it could only fund operations for 12 months. Following this disclosure, ZBIO shares dropped nearly 49%, closing at $8.72 as of April 15, 2025. Why Lead Plaintiff Status Matters The lead plaintiff acts on behalf of all class members in directing the litigation, including case strategy and settlement discussions. While not required to recover damages, investors with significant losses often choose to serve in this leadership role to oversee the vigorous prosecution of the case. Cohen Milstein’s Record of Results Cohen Milstein is one of the country’s most highly regarded plaintiffs’ securities firms in the U.S. Annually, the firm and the securities litigation practice recognized by The Legal 500, Law360, Chambers USA, and The National Law Journal as a leader in high-impact securities class action. The firm recently served as co-lead counsel in In re Wells Fargo Securities Litigation, securing a $1 billion settlement for defrauded investors. CONTACT: Molly Bowen, Esq. Licensed in DC, Florida, and Ohio Cohen Milstein Sellers & Toll PLLC 1100 New York Avenue, N.W., Fifth Floor Washington, D.C. 20005 Phone: (888) 240-0775 or (202) 408-4600 Email: [email protected] Website: www.cohenmilstein.com Attorney Advertising. Prior results do not guarantee a similar outcomes.
Cohen Milstein Continues Lead Plaintiff Search for Zenas BioPharma (ZBIO) Securities Fraud Class Action Following Post-IPO Stock Decline
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...